Mood disorder

Stellate Ganglion Block Treatment in Bay Area Launched by Soft Reboot Wellness

Retrieved on: 
Thursday, February 9, 2023
Attention deficit hyperactivity disorder predominantly inattentive, PTSD, Injection, Hypervigilance, Neck, Insomnia, Mountain View, Interest, Trauma, Soft reboot, SGB, Sympathetic nervous system, Irritability, Anxiety, Mood disorder, Music, Depression, Mental health, Pharmaceutical industry, Meat

Soft Reboot Wellness (+1 650-419-3330), a holistic therapy center in the Bay Area, has launched Stellate Ganglion Block (SGB) treatment for PTSD and mood disorders.

Key Points: 
  • To view an enhanced version of this graphic, please visit:
    Therapists at Soft Reboot Wellness explain that a traumatic event can cause the stellate ganglion to become hyperactive, causing trauma symptoms such as depression, anxiety, insomnia, hypervigilance, irritability, and others.
  • Although SGB is not considered a cure for PTSD symptoms, professionals at Soft Reboot Wellness believe the new treatment can bring meaningful relief that can last for months.
  • Soft Reboot Wellness explains that SGB treatment can provide clients with relief from the physical symptoms of PTSD within days.
  • Soft Reboot Wellness is run by Dr. Sara Herman, who has been serving Bay Area cities including Menlo Park, Palo Alto, Mountain View, and Los Altos for over 12 years.

EQS-News: Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer

Retrieved on: 
Sunday, January 22, 2023
Psilocybin, Cancer, Mood disorder, Mental health, Anxiety, Commercial, Biotechnology, Innes, Learned helplessness, Research, Addiction medicine, Depression, Orexo, Series, CNS, Growth, Patient, Novartis, Psychotherapy, Demoralization, Grammatical mood, Chairperson, Senior, Pharmaceutical industry

New York, NY, January 5, 2023 - Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.

Key Points: 
  • New York, NY, January 5, 2023 - Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
  • Innes Meldrum has nearly 30 years of global experience in the biotechnology and technology industries, having most recently served as Senior Vice President and Chief Commercial Officer for Otsuka Pharmaceuticals North America.
  • “We are delighted to have Innes join Reset Pharma as CEO,” said Philip Taub, Chair of the Board.
  • I warmly welcome Innes and look forward to working with him and the entire Reset Pharma team.

Reset Pharmaceuticals Appoints Innes Meldrum as President and Chief Executive Officer

Retrieved on: 
Thursday, January 5, 2023
Psilocybin, Cancer, Mood disorder, Mental health, Anxiety, Commercial, Biotechnology, Innes, Learned helplessness, Research, Addiction medicine, Depression, Orexo, Series, CNS, Growth, Patient, Novartis, Psychotherapy, Demoralization, Grammatical mood, Chairperson, Senior, Pharmaceutical industry

NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.

Key Points: 
  • NEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Reset Pharmaceuticals, Inc. (Reset Pharma), a privately held biotechnology company focused on the development of innovative treatments to address mental health indications related to life-altering diseases, today announces that Innes Meldrum has been appointed President and Chief Executive Officer.
  • Innes Meldrum has nearly 30 years of global experience in the biotechnology and technology industries, having most recently served as Senior Vice President and Chief Commercial Officer for Otsuka Pharmaceuticals North America.
  • “We are delighted to have Innes join Reset Pharma as CEO,” said Philip Taub, Chair of the Board.
  • I warmly welcome Innes and look forward to working with him and the entire Reset Pharma team.

Otsuka and Sunovion Initiate Clinical Development of Ulotaront for the Adjunctive Treatment of Major Depressive Disorder

Retrieved on: 
Thursday, December 1, 2022
Mental Health, Health, Other Health, Clinical Trials, General Health, Pharmaceutical, Mental health, Psychiatry, Science, Commercialization, Regulation of tobacco by the U.S. Food and Drug Administration, Global Burden of Disease Study, Sunovion, Grammatical mood, Cardiology, MDD, Algorithm, Patient, Heart, Education, Creativity, Psychology, Maintenance, Medicine, Medication, OAPI, Health, Oncology, Trial of the century, FDA, Food, SUNOVION, Disease, Depression, Tuberculosis, The Lancet, Research, MADRS, TAAR1, Safety, Schizophrenia, Breakthrough therapy, Multimedia, Mood disorder, Investment, Disability, Nephrology, Pharmaceutical industry, Fine chemical

Ulotaront, which is also being evaluated in Phase 3 clinical development for the treatment of schizophrenia, is the first TAAR1 agonist to be studied as an adjunctive therapy in the treatment of MDD.

Key Points: 
  • Ulotaront, which is also being evaluated in Phase 3 clinical development for the treatment of schizophrenia, is the first TAAR1 agonist to be studied as an adjunctive therapy in the treatment of MDD.
  • Ulotaront was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in 2019.
  • Its also the first TAAR1 agonist to enter into a Phase 2/3 clinical study as an adjunctive therapy for MDD.
  • Major depressive disorder is a chronic debilitating disease characterized by symptoms that last at least two weeks causing significant functional impairment.

Neuromodulation Devices Markets, 2029 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 28, 2022
Medical Devices, Health, Neurology, Other Science, Science, Biotechnology, Webbed toes, Hypoglossal nerve, Hospital, Incidence, TENS, Neuromodulation, Gastroenterology, Degenerative disease, Pain management, SCS, Weaning, Stroke, Epilepsy, Chronic pain, Patient, Anxiety, Government, OSA, Ageing, Heart failure, Parkinson's disease, Transcutaneous electrical nerve stimulation, Obesity, Rheumatoid arthritis, CNS, Autoimmune disease, Central sleep apnea, Obstructive sleep apnea, Functional electrical stimulation, Diabetes, Mood disorder, Obsessive–compulsive disorder, Multiple sclerosis, Urinary incontinence, Urology, OCD, NMES, Movement disorders, Central nervous system, Investment, Pharmaceutical industry, Medical device, Beauty salon, Medicine, Dystonia, Depression, Gastroparesis

The "Neuromodulation Devices Global Market- Forecast To 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neuromodulation Devices Global Market- Forecast To 2029" report has been added to ResearchAndMarkets.com's offering.
  • The treatment delivered by neuromodulation devices brings about life-changing transformation in patients who fail to get better by traditional approaches.
  • Based on the product, the neuromodulation global market is segmented into invasive neuromodulation devices and non-invasive neuromodulation devices.
  • Among these, invasive neuromodulation devices segment accounted for the highest revenue in 2022 and is expected to grow at an early teen CAGR from 2022 to 2029.

Elysian Wellness: Veteran Owned Ketamine Clinic Celebrates 1-Year Anniversary

Retrieved on: 
Friday, November 11, 2022
Alternative Medicine, Mental Health, Health, Defense, Pharmaceutical, Veterans, Elysian, PTSD, Quality of life, Health, Depression, Navy, Mental, Anxiety, Population, Wellness, Mental health, United States Navy Veterans Association, Chronic pain, Anesthesia, Mood disorder, Ketamine, Physician, Patient, Growth, Suicidal ideation, Medicine, Pharmaceutical industry, Elysium, Hampton Roads

Elysian enters its second year of business serving the Hampton Roads community by offering ketamine therapy for those suffering from depression, anxiety, PTSD, suicidal ideations, and chronic pain.

Key Points: 
  • Elysian enters its second year of business serving the Hampton Roads community by offering ketamine therapy for those suffering from depression, anxiety, PTSD, suicidal ideations, and chronic pain.
  • Elysian Wellness is the only practice in Hampton Roads that is run exclusively by Navy Veterans.
  • Our personal experience with fellow uniformed service members and their families inspired us to open Elysian Wellness.
  • Ketamine therapy has proven effective at Elysian Wellness; we have provided relief to more than 80 % of our patients.

EQS-News: Reset Pharmaceuticals announces appointment of neuroscience industry leader Lisa Deschamps to the Board of Directors

Retrieved on: 
Thursday, November 3, 2022
Depression, MBA, Frontotemporal dementia, Cancer, CNS, Board, Learned helplessness, Risk, ALS, Anxiety, Novartis Gene Therapies, Central Waqf Council, Novartis, Psilocybin, Strategic planning, Patient, Neurodegeneration, Mood disorder, FTD, Psychiatry, Grammatical mood, Forward-looking statement, Amyotrophic lateral sclerosis, Mental health, Demoralization, Suicide, Coronavirus Scientific Advisory Board (Turkey), Pharmaceutical industry, Neuroscience

Ms. Deschamps is a highly experienced pharmaceutical executive who has worked at Board and senior management levels with global responsibilities.

Key Points: 
  • Ms. Deschamps is a highly experienced pharmaceutical executive who has worked at Board and senior management levels with global responsibilities.
  • Before this, she was Worldwide Business Head, Neuroscience at Novartis, where she was responsible for the development and commercialization of the neuroscience portfolio.
  • She has been involved in more than a dozen successful product approvals and launches in many therapeutic areas, including in neuroscience.
  • We are very happy to welcome Lisa to the Board, said Philip Taub, Chair of the Board of Reset Pharma.

Reset Pharmaceuticals announces appointment of neuroscience industry leader Lisa Deschamps to the Board of Directors

Retrieved on: 
Wednesday, November 2, 2022
Depression, MBA, Frontotemporal dementia, Cancer, CNS, Board, Learned helplessness, GLOBE, Risk, ALS, Anxiety, Central Waqf Council, Novartis Gene Therapies, Novartis, Psilocybin, Strategic planning, Patient, Neurodegeneration, Mood disorder, FTD, Psychiatry, Grammatical mood, Forward-looking statement, Amyotrophic lateral sclerosis, Mental health, Demoralization, Suicide, Coronavirus Scientific Advisory Board (Turkey), Pharmaceutical industry, Neuroscience

Ms. Deschamps is a highly experienced pharmaceutical executive who has worked at Board and senior management levels with global responsibilities.

Key Points: 
  • Ms. Deschamps is a highly experienced pharmaceutical executive who has worked at Board and senior management levels with global responsibilities.
  • Before this, she was Worldwide Business Head, Neuroscience at Novartis, where she was responsible for the development and commercialization of the neuroscience portfolio.
  • She has been involved in more than a dozen successful product approvals and launches in many therapeutic areas, including in neuroscience.
  • We are very happy to welcome Lisa to the Board, said Philip Taub, Chair of the Board of Reset Pharma.

Clinical Research by Salem Anaesthesia Pain Clinic, Surrey, Canada, Shows That Clonidine is Better Than Zopiclone for Insomnia Treatment

Retrieved on: 
Wednesday, November 2, 2022
Patient safety, Health, Xerostomia, Gamma-Aminobutyric acid, Attention deficit hyperactivity disorder predominantly inattentive, Clonidine, Fatigue, Brain, Research, Hallucination, GLOBE, Hypertension, Drug, Insomnia, Safety, Nightmare, Anxiety, Amnesia, Bruxism, Journal, Patient, Mood disorder, Confusion, Benzodiazepine, Falls, Addiction, Headache, Depression, Chronic pain, Dentistry, Pharmaceutical industry

SURREY, British Columbia, Nov. 02, 2022 (GLOBE NEWSWIRE) -- A clinical research study has shown that Clonidine is better than Zopiclone for insomnia treatment in chronic pain patients.

Key Points: 
  • SURREY, British Columbia, Nov. 02, 2022 (GLOBE NEWSWIRE) -- A clinical research study has shown that Clonidine is better than Zopiclone for insomnia treatment in chronic pain patients.
  • The critically acclaimed research was led and authored by Dr. Olu Bamgbade at the Salem Anaesthesia Pain Clinic in Surrey, British Columbia, Canada.
  • Dr. Olu Bamgbade is the director of the Salem Anaesthesia Pain Clinic, a specialist pain clinic and research center( https://salempainclinic.net/ ).
  • Based in Surrey, British Columbia, Canada, Salem Anaesthesia Pain Clinic is aspecialist pain clinic and research center that provides multimodal pain management, interventional pain treatment, substance misuse therapy, insomnia treatment and preoperative optimization therapy.

COVID-19 was one of the costliest medical conditions in 2021, with the highest claim reaching $1.75 million, Sun Life claims data shows

Retrieved on: 
Tuesday, June 21, 2022
Sun Life Financial, Comorbidity, Burns, Kaiser Foundation, COVID-19, Disability, TSX, Mood disorder, Research, Insurance, Pharmacy, Sepsis, Cancer, Birth, Malnutrition, Health Navigator, Haemophilia, Growth, Mental health, Annual report, Health, SLF, Bermuda, United Kingdom, Hospital, PSE, NYSE, Risk, Life, Dietary supplement, Health insurance, Pharmaceutical industry, Animal, Financial services

WELLESLEY, Mass., June 21, 2022 /PRNewswire/ -- Sun Life U.S. has released its 10th annual report on high-cost medical claims, analyzing its stop-loss claims data and medical trends from 2018 – 2021. COVID-19 rose to a top 10 costliest condition in 2021, with the highest-cost COVID-19 claim reaching $1.75 million. Other categories of medical claims, including cancer and mental health claims, showed increases as well. The report reviewed nearly 50,000 Sun Life member claims from more than 2,800 self-funded employer clients around the country, providing research and data indicative of U.S. healthcare trends. The rise in claims over the study period are the result of increases in underlying medical claims cost as well as changes to Sun Life's book of covered business.

Key Points: 
  • COVID-19 rose to a top 10 costliest condition in 2021, with the highest-cost COVID-19 claim reaching $1.75 million.
  • Other categories of medical claims, including cancer and mental health claims, showed increases as well.
  • Sun Life also provides members with health advisory and care navigation services through its Health Navigator solution, powered by PinnacleCare.
  • COVID-19 claims that were severe enough to breach stop-loss deductibles averaged $231,300, with the highest claim at $1.75 million.